drugset / Trial / NCT02076477
The Optimal Intervention Time of Radiotherapy for Oligometastatic Stage IV Non-small Cell Lung Cancer（NSCLC）
Phase 3
Unknown
420 enrolled
Sichuan Cancer Hospital and Research Institute
Cancer Hospital of Guizhou Province · collabMianyang Central Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study evaluates the optimal intervention time of radiotherapy for oligometastatic stage iv lung cancer.
Timeline
- Start
- 2014-01
- Primary completion
- 2020-10
- Completion
- 2020-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 25 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | 60 mg/m2 | Intravenous |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |